Sanofi
SNY
623 hedge funds and large institutions have $12.8B invested in Sanofi in 2022 Q1 according to their latest regulatory filings, with 67 funds opening new positions, 241 increasing their positions, 175 reducing their positions, and 58 closing their positions.
445% more call options, than puts
Call options by funds: $82.9M | Put options by funds: $15.2M
38% more repeat investments, than reductions
Existing positions increased: 241 | Existing positions reduced: 175
16% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 58
5% more capital invested
Capital invested by funds: $12.2B → $12.8B (+$565M)
0.59% more ownership
Funds ownership: 19.34% → 19.93% (+0.59%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
0% less funds holding
Funds holding: 624 → 623 (-1)
Top Buyers
Top Sellers
| 1 |
Dodge & Cox
San Francisco,
California
|
-$72M |
| 2 |
Morgan Stanley
New York
|
-$64.9M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$51.5M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$25.2M |
| 5 |
SG Americas Securities
New York
|
-$22.3M |
SNY Hedge Fund Activity: Q1 2022 in Review
623 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q1 2022, worth a combined $12.8B — up 4.6% from $12.2B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new SNY positions and 58 closed out — a net gain of 9 holders — while 241 added to existing stakes and 175 trimmed.
The largest buyer was Boston Partners, adding an estimated $224M. The largest seller was Dodge & Cox, cutting an estimated $72M.
- 623 institutional investors held Sanofi (SNY) as of Q1 2022, down from 624 in Q4 2021.
- Funds reported $12.8B of Sanofi stock for Q1 2022, up 4.6% quarter-over-quarter.
- 67 funds opened new Sanofi positions in Q1 2022 and 58 closed out, a net change of +9 holders.
- The largest Sanofi buyer in Q1 2022 was Boston Partners, an estimated $224M added.
- The largest Sanofi seller in Q1 2022 was Dodge & Cox, an estimated $72M sold.
Based on aggregated 13F filings for Q1 2022.